Table 1. Patient information and genetic background.

Patient	PSA at diagnosis (ng/mL)	Gleason score	Pathological Score	BMI	Genetic Background/Status
					PTEN	MYC	ERG	Nkx3.1
1	3.6	(4 + 3) 7	pT3a	24	Loss	Amplification1	Negative	Positive
2	5.8	(3 + 4) 7	pT3a	32	Low expression	Negative	Positive	Positive
3	n/a	(4 + 4) 8	pT3a	29	High expression	Negative	Negative	Positive
4*	6.6	(3 + 4) 7	pT2c	30	Low expression	Negative	Negative	Positive
5*	4.8	(4 + 3) 7	pT3a	26	Low expression	Amplification1	Positive	Positive
6*	11.6	(4 + 3) 7	pT3a	26	Low expression	Negative	Negative	Positive

Patients 1–3 were used for study 1 (PDX in HFD and LFD).

Patients 4–6 were used for study 2 (PDX of prostate cancer + PPAT).

^*Prostate cancer and PPAT samples were obtained from patients 4–6.

pT2c = Tumour is confined within the prostate but involves both lobes.

pT3a = Tumour has undergone extracapsular extension.

¹Amplification leading to expression detected by immunohistochemistry.